Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2013-04-05
Adverse events
Moderate APPLICATION SITE BLEEDING — outcome: RECOVERED/RESOLVED; onset 2013-06-07 (study day 64.0); relationship: PROBABLE
Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-01 (study day 27.0); relationship: PROBABLE
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-01 (study day 27.0); relationship: PROBABLE
Mild COUGH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-07-12 (study day 99.0); relationship: NONE
Mild SYNCOPE — outcome: RECOVERED/RESOLVED; onset 2013-05-21 (study day 47.0); relationship: POSSIBLE; serious criteria: hospitalization
Mild VOMITING — outcome: RECOVERED/RESOLVED; onset 2013-05-21 (study day 47.0); relationship: POSSIBLE
Data queries
No data queries.